Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its Mindscape Ketamine & Infusion Therapy, PLLC subsidiary has treated its 1,000th patient with IV Ketamine Therapy for treatment-resistant mood disorders, mental health disorders and chronic pain conditions.
The mental healthcare company said the clinic reached the patient milestone in less than two years since its acquisition by Wellbeing, demonstrating the great need for this breakthrough treatment.
“In addition to the Clinic’s remarkable efficiency and reduction in treatment times, the clinical advantages of IV Ketamine therapy have also become increasingly evident,” Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) CEO Najla Guthrie said in a statement.
READ: Wellbeing Digital Sciences appoints Mohammad Sharifi to its board of directors
“We believe ketamine infusion therapy is the future of treating depression and can be a new light to a person whom other treatment options have failed,” Guthrie added.
Ketamine is an anesthetic that has been used for over 50 years and is now being investigated across the nation as an off-label treatment of psychiatric disorders and pain conditions, Wellbeing noted.
It pointed out that Mindscape aims to help facilitate patient healing using low-dose IV ketamine treatments.
Mindscape is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders, according to the company.
Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.
A subsidiary of Wellbeing Digital, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging healthcare products.
Contact Sean at sean@proactiveinvestors.com